IN THE CLAIMS

Please cancel claims 1-11 and 13-118.

Insert new claims 119-177, as follows:

119. (NEW) A pharmaceutical composition for oral administration to a mammalian subject, comprising: a taxane and a vehicle comprising at least about 30% by weight of a carrier having an HLB value at least about 10, and from about 5-70% by weight of a co-solubilizer in which at least 25 mg/ml of the taxane can be solubilized at about 20-25°C.

B1 120. (NEW) The composition of claim 119 wherein said vehicle further comprises at least one non-ionic surfactant or emulsifier.

121. (NEW) The composition of claim 120 wherein said surfactant or emulsifier is selected from the group consisting of Vitamin E TPGS, saturated polyglycolyzed glycerides, modified castor oils, polyoxyethylated stearate esters, polyoxyethylated sorbitan esters, polyoxyethylated fatty ethers, modified almond and corn oil glycerides, sorbitan diisostearate esters, polyoxyethylated hydroxystearates, and β-cyclodextrin.

122. (NEW) The composition of claim 121 wherein said saturated polyglycolyzed glycerides include glycerides of C_8 - C_{18} fatty acids.

123. (NEW) The composition of claim 121 wherein said modified castor oils are polyoxyethylated or hydrogenated castor oils.

124. (NEW) The composition of claim 121 wherein said polyoxyethylated fatty ethers are stearyl or oleyl ethers.

125. (NEW) The composition of claim 121 wherein said modified almond and corn oil glycerides comprise polyethylene glycol almond or corn oil glycerides.

126. (NEW) The composition of claim 119 wherein said vehicle comprises about 30 - 90% by weight of said carrier.

127. (NEW) The composition of claim 119 wherein said taxane is dissolved or dispersed in the vehicle.

128. (NEW) The composition of claim 119 wherein the concentration of said taxane in the vehicle is about 2 - 500 mg/ml or mg/g.

129. (NEW) The composition of claim 119 wherein the concentration of said taxane in the vehicle is about 2 - 50 mg/ml or mg/g.

130. (NEW) The composition of claim 119 wherein said vehicle comprises about 10 - 50% by weight of said co-solubilizer.

131. (NEW) The composition of claim 121 wherein said surfactant or emulsifier is Vitamin E TPGS.

132. (NEW) The composition of claim 119 wherein said co-solubilizer is selected from the group consisting of N-methyl-2-pyrrolidone, glycerol or propylene glycol esters of caprylic and capric acids, polyoxyethylated hydroxystearates, polyoxyethylated sorbitan esters, polyethylene glycol esters of caprylic and capric acids, modified castor oils, vegetable oils, saturated polyglycolyzed glycerides, citrate esters, propylene glycol, ethanol, water and lower molecular weight polyethylene glycols.

B1 cont

133. (NEW) The composition of claim 132 wherein said modified castor oils comprise polyoxyethylated or hydrogenated castor oils.

134. (NEW) The composition of claim 132 wherein said vegetable oils comprise olive oil.

135. (NEW) The composition of claim 132 wherein said saturated polyglycolyzed glycerides comprise glycerides of C_8 - C_{18} fatty acids.

136. (NEW) The composition of claim 132 wherein said citrate esters comprise tributyl citrate, triethyl citrate or acetyl triethyl citrate.

137. (NEW) The composition of claim 132 wherein said lower molecular weight polyethylene glycols comprise PEG 200 or PEG 400.

138. (NEW) The composition of claim 132 wherein said co-solubilizer comprises a saturated polyglycolyzed glyceride.

139. (NEW) The composition of claim 138 wherein said saturated polyglycolyzed glyceride is a glyceride of a C_8 - C_{18} fatty acid.

140. (NEW) The composition of claim 121 wherein said surfactant or emulsifier is selected from polyoxyethylated stearate esters.

141. (NEW) The composition of claim 131 wherein said co-solubilizer comprises N-methyl-2-pyrrolidone.

142. (NEW) The composition of claim 131 wherein said co-solubilizer comprises ethanol.

143. (NEW) The composition of claim 119 which, when ingested orally by a mammal one hour after ingestion of an effective oral dose of an oral bioavailability enhancing agent, provides absorption of said taxane from the mammal's gastrointestinal tract into the bloodstream at a level which is at least 15% of the level of absorption achieved when the same amount of said taxane is administered to the mammal by intravenous injection in a pharmaceutically acceptable intravenous vehicle.

144. (NEW) The composition of claim 143 wherein said bioavailability enhancing agent is a cyclosporin.

145. (NEW) The composition of claim 144 wherein said cyclosporin is cyclosporin A.

146. (NEW) The composition of claim 119 wherein said taxane is paclitaxel or docetaxel.

147. (NEW) The composition of claim 146 wherein said taxane is paclitaxel.

148. (NEW) The composition of claim 119 wherein said carrier comprises polyoxyethylated (POE) 660 hydroxystearate.

149. (NEW) The composition of claim 148 wherein said carrier comprises a saturated polyglycolized glyceride.

150. (NEW) The composition of claim 149 wherein said co-solubilizer comprises a saturated polyglycolized C8-C10 glyceride.

151. (NEW) The composition of claim 149 wherein said co-solubilizer comprises a lower molecular weight polyethylene glycol.

152. (NEW) The composition of claim 149 wherein said co-solubilizer comprises a modified castor oil.

153. (NEW) The composition of claim 119 wherein said carrier comprises vitamin E TPGS.

B1 Cont

154. (NEW) The composition of claim 153 wherein said co-solubilizer comprises propylene glycol.

155. (NEW) An oral pharmaceutical dosage form comprising the pharmaceutical composition of claim 119.

156. (NEW) The dosage form of claim 155 which comprises a liquid preparation.

157. (NEW) The dosage form of claim 155 wherein said pharmaceutical composition is encapsulated in a soft or hard gelatin capsule.

158. (NEW) The dosage form of claim 155 further comprising a pharmaceutical excipient, diluent, sweetener, flavoring agent or coloring agent.

159. (NEW) The dosage form of claim 155 wherein said taxane is paclitaxel or docetaxel.

160. (NEW) The dosage form of claim 155 wherein said taxane is paclitaxel.

161. (NEW) The dosage form of claim 155 which contains about 20 - 1000 mg/m^2 of said taxane based on the body surface area of the mammalian subject.

162. (NEW) The dosage form of claim 155 which contains about 50 - 200 mg/m^2 of said taxane based on the body surface area of the mammalian subject.

163. (NEW) The dosage form of claim 155 which contains about 0.5 - 30 mg/kg of said taxane based on the weight of the mammalian subject.

164. (NEW) The dosage form of claim 155 which contains about 2 - 6 mg/kg of said taxane based on the weight of the mammalian subject.

165. (NEW) A two-part medicament for oral administration to a mammalian subject, the first part of said medicament comprising a taxane, and the second part of said medicament comprising a vehicle comprising a carrier having an HLB value at least about 10, and a co-solubilizer that can solubilize at least 25 mg/ml of the taxane at about 20-25 °C, wherein amount of said carrier is at least 30% by weight of vehicle and wherein amount of said co-solubilizer is from 5-70% by weight of said vehicle.

166. (NEW) The two-part medicament of claim 165 wherein said first part of said medicament further comprises water, ethanol or a polyoxyethylated or hydrogenated castor oil.

167. (NEW) The two-part medicament of claim 165 wherein said solubilizing vehicle comprises a sweetening agent, flavoring agent or coloring agent.

168. (NEW) The two-part medicament of claim 165 wherein said first part of said medicament contains about 2 - 500 mg/ml or mg/g of the taxane.

169. (NEW) The two-part medicament of claim 165 wherein said first part of said medicament contains about 2 - 50 mg/ml or mg/g of the taxane.

170. (NEW) The two-part medicament of claim 165 wherein said vehicle further comprises at least one non-ionic surfactant or emulsifier.

171. (NEW) The two-part medicament of claim 165 wherein said vehicle further comprises at least one surfactant or emulsifier selected from the group consisting of Vitamin E TPGS, saturated polyglycolyzed glycerides, modified castor oils, polyoxyethylated stearate esters, polyoxyethylated sorbitan esters, polyoxyethylated fatty ethers, modified almond and corn oil glycerides, sorbitan diisostearate esters, polyoxyethylated hydroxystearates, and β-cyclodextrin.

172. (NEW) The two-part medicament of claim 165 wherein the second part of the medicament comprises about 30-240 ml of fluid.

B1 cut

173. (NEW) The two-part medicament of claim 165 wherein said taxane is paclitaxel or docetaxel.

174. (NEW) The two-part medicament of claim 165 wherein said taxane is paclitaxel.

175. (NEW) The two-part medicament of claim 165 wherein said carrier comprises Vitamin E TPGS.

176. (NEW) The two-part medicament of claim 165 wherein said co-solubilizer is N-methyl-2-pyrrolidone.

177. (NEW) The two-part medicament of claim 165 wherein said co-solubilizer is propylene glycol.